Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045514 | 1.00 | MAPK14 (0.38) | MAPK14KLKB1PLAUF10CTSD | |
| SCHEMBL5043455 | 0.92 | NPC1 (0.38) | PLAUF10CTSD | |
| SCHEMBL5043453 | 0.92 | NPC1 (0.38) | PLAUF10CTSD | |
| SCHEMBL6068650 | 0.88 | PLAU (0.36) | PLAUF10 | |
| SCHEMBL6068653 | 0.88 | PLAU (0.36) | PLAUF10 | |
| SCHEMBL5041098 | 0.88 | PLAU (0.39) | PLAUF10CTSDCARM1 | |
| SCHEMBL5041095 | 0.88 | PLAU (0.39) | PLAUF10CTSDCARM1 | |
| SCHEMBL5045458 | 0.87 | ALDH1A1 (0.40) | PLAUF10CTSDCARM1 | |
| SCHEMBL5045460 | 0.87 | ALDH1A1 (0.40) | PLAUF10CTSDCARM1 | |
| SCHEMBL5037326 | 0.86 | PLAU (0.46) | PLAUF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | MAPK14 1193/4885KLKB1 216/4885PLAU 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.